-
Hua Medicine’s Second-Generation GKA HM-002-1005 Completes Phase Ia Study in the US
•
China-based Hua Medicine (HKG: 2552) has announced the successful completion of a Phase Ia study for its second-generation glucokinase activator (GKA) HM-002-1005 in the United States. The study focused on the safety, tolerability, and pharmacokinetics of HM-002-1005, a prodrug of dorzagliatin (HMS5552), in 40 subjects with type 2 diabetes (T2D).…
-
Hua Medicine and Bayer AG Terminate Co-promotion Agreement for HuaTangNing
•
China-based Hua Medicine (HKG: 2552) has announced the termination of its co-promotion agreement with German pharmaceutical giant Bayer AG (ETR: BAYN) regarding HuaTangNing (dorzagliatin tablets, HMS5552), effective January 1, 2025. The agreement, which began in August 2020, focused on the promotion and distribution of the drug in China. Dorzagliatin’s Impact…
-
Hua Medicine’s 2024H1 Revenues Surge on HuaTangNing Sales; Path to Profitability in Sight
•
HONG KONG—Hua Medicine (HKG: 2552), a China-based pharmaceutical company, has announced its financial results for the first half of 2024, reflecting a 46.0% year-on-year increase in revenues, which reached RMB 102.7 million. This growth is primarily attributed to the strong performance of its flagship hypoglycemic agent, HuaTangNing (dorzagliatin tablets). Despite…
-
Hua Medicine Reports 2023 Revenues of RMB 76.6 Million, Driven by Hypoglycemic Agent HuaTangNing
•
China-based biopharmaceutical company Hua Medicine (HKG: 2552) has released its financial report for 2023, with revenues amounting to RMB 76.6 million (USD 10.57 million), primarily from its core product, HuaTangNing (dorzagliatin tablets), an oral hypoglycemic agent. The revenues were generated from the sale of 251,000 boxes of the drug since…
-
Hua Medicine Achieves Development Milestone for HuaTangNing with Bayer Agreement
•
China-based Hua Medicine (HKG: 2552) has announced the achievement of a significant development milestone for its diabetes treatment, HuaTangNing (dorzagliatin tablets, HMS5552). According to the terms of the 2020 collaboration agreement with Bayer AG (ETR: BAYN) focused on dorzagliatin, Hua is now eligible to receive a new milestone payment of…
-
Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China
•
China-based Hua Medicine (HKG: 2552) has announced a sales and distribution agreement with online pharma retailer 111 Inc., enabling the latter to sell Hua Medicine’s dorzagliatin on its platform from April 7, 2023, to December 31, 2023. Hua Medicine will charge a fee of not more than RMB 40 million…
-
Hua Medicine’s Dorzagliatin Approved in China for Type 2 Diabetes
•
China-based Hua Medicine (HKG: 2552) has announced that its Category 1 drug dorzagliatin has been approved by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with type 2 diabetes. The first-in-class oral hypoglycemic drug represents an innovative treatment option for patients in China. Approval Based…
